When was Virchow Biotech founded?

Virchow Biotech was founded in 2001.

Where is Virchow Biotech located?

Virchow Biotech is headquartered in Hyderabad, India. It is registered at PLOT NO.4,SV CO OP INDUSTRIAL ESTATE, IDA, JEEDIMETLA, \HYDERABAD-55, Telangana, India, 000000.

Who is the current CEO of Virchow Biotech?

Ravi Kumar Gattupalli of Virchow Biotech.

Which legal entities is Virchow Biotech associated with?

Virchow Biotech is associated with VIRCHOW BIOTECH PRIVATE LIMITED.

How many employees does Virchow Biotech have?

As of Aug 31, 2025, Virchow Biotech has 1188 employees, reflecting a 3% year-over-year decline in headcount.

Is Virchow Biotech a funded company?

Virchow Biotech is a funded company, having raised a total of $***** in its 1st and only funding round, a Grant (prize money) round.

When was the latest funding round of Virchow Biotech?

Virchow Biotech's latest funding was a $***** Grant (prize money) round, with participation from 1 investor. Its primary sector is Diversified Pharmaceuticals. Globally, the Diversified Pharmaceuticals sector has seen $270M in funding in 2026 to date.

What is the annual revenue of Virchow Biotech?

Annual revenue of Virchow Biotech is ₹758Cr as on Mar 31, 2025.

Where does Virchow Biotech rank among its competitors?

Virchow Biotech ranks 202nd amongst 1284 active competitors, of which 75 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Johnson & Johnson, which secured $34M in Feb, 2025.

Who are the top competitors of Virchow Biotech?

Virchow Biotech's top competitors include AbbVie, Amgen and Gilead. Among them, Johnson & Johnson secured the most recent funding round in February, 2025.

Virchow Biotech - 2026 Company Profile, Team, Funding, Competitors & Financials

Virchow Biotech is a funded company based in Hyderabad (India), founded in 2001 by Hemanth Nandigala and Murali KR Tummuru. It operates as a Recombinant products for wound care, osteoporosis & periodontal disorders. Virchow Biotech has raised an undisclosed amount in funding. The company has 1284 active competitors, including 75 funded and 157 that have exited. Its top competitors include companies like AbbVie, Amgen and Gilead.

Company Details

Virchow Biotech is focussed developing biologicals and biogeneric products. It is focussed on the development of products based on recombinant DNA and molecular biology. It developed two bio-generic human therapeutics, Healace (rh PDGF-BB, marketed in India as Plermin by Dr. Reddy's) and Osteotide (marketed in India as Bonista by Ranbaxy). Its product portfolio consists of 15 bio-generic products covering wound care and haemostasis, ophthalmology, orthopedics, probiotics and gastroenterology. It also has five other recombinant bio-generics in the pipeline. It is filing for US FDA approval for its developed advanced wound care products and has received Drug control’s (DCGI) approval for conducting clinical trials on periogen, a recombinant therapeutic product for periodontal diseases.

Website: virchowbiotech.com
Email ID: *****@virchowbiotech.com
Phone Number: +91 **********
Registered Address: PLOT NO.4,SV CO OP INDUSTRIAL ESTATE, IDA, JEEDIMETLA, \HYDERABAD-55, Telangana, India, 000000

Key Metrics

Founded Year

2001

Location

Hyderabad, India

Stage

Funding Raised

Latest Funding Round

Grant (prize money), $*****

Investors

Department of Biotechnology & 1 more

Ranked

202^nd among 1284 active competitors

Annual Revenue

₹758Cr as on Mar 31, 2025

Employee Count

1,188 as on Aug 31, 2025

Similar Companies

AbbVie & 1310 more

View Virchow Biotech's full profile

Virchow Biotech is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
VIRCHOW BIOTECH PRIVATE LIMITED CIN: U24210TG2001PTC036520 , India, Active	Apr 04, 2001	$89.7M (As on Mar 31, 2025)	1188 (As on Aug 01, 2025)

Virchow Biotech has raised funding over 1 round. Its latest funding round was a Grant (prize money) round. 1 investor participated in its latest round. Virchow Biotech has 2 institutional investors.

View details of Virchow Biotech's funding rounds and investors

The founders of Virchow Biotech are Hemanth Nandigala and Murali KR Tummuru. Ravi Kumar Gattupalli is the CEO of Virchow Biotech.

Here are the details of Virchow Biotech's key team members:

Hemanth Nandigala: Co-Founder of Virchow Biotech. They serve on the board of 1 company.
Contact Info: 1 email address
Murali KR Tummuru: Co-Founder of Virchow Biotech. They serve on the board of 1 company.
Contact Info: 1 email address
Ravi Kumar Gattupalli: CEO of Virchow Biotech.

Virchow Biotech's Board of Directors

Virchow Biotech's board has 4 active members. Hemanth Nandigala and Murali KR Tummuru are part of team and Prasanth Nandigala and Mundla Maha Vishnu are independent board members.

Here is the list of Virchow Biotech's board of directors:

Name	Type	Representing	Status	Duration
Hemanth Nandigala	Team	-	Current	25y 1m
Murali KR Tummuru	Team	-	Current	24y 5m
Prasanth Nandigala	Independent board member	-	Current	2y 4m
xv{tvhp	Independent board member	-	Current	3y 2m

View details of Virchow Biotech's Founder profiles and Board Members

Virchow Biotech's employee count trend

Virchow Biotech has 1,188 employees as of Aug 25. The total employee count is 4.0% lower than what it was in Aug 24. Here is Virchow Biotech's employee count trend over the years:

Employee count trend for Virchow Biotech

Uncover Virchow Biotech's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Virchow Biotech include AbbVie, Amgen and Gilead. Here is the list of Top 10 competitors of Virchow Biotech, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AbbVie 2012, Chicago (United States), Public	Research-based biopharmaceutical company	$14.7B	Alcor Fund, Berkshire Hathaway & 8 others	81/100
2nd	Amgen 1980, Thousand Oaks (United States), Public	Developer of pharmaceutical products for treating multiple diseases	-	Amgen Business Development, Gershon Capital ... & 11 others	81/100
3rd	Gilead 1987, Foster City (United States), Acquired	Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others	-	BB Biotech, Temasek & 17 others	80/100
4th	Lilly 1876, Indianapolis (United States), Public	Developer of traditional pharmaceutical medicines	-	Alcor Fund, Gershon Capital & 11 others	79/100
5th	Johnson & Johnson 1886, New Brunswick (United States), Public	Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products	-	Alcor Fund, Western Technology Investment ... & 16 others	76/100
6th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	BB Biotech, RA Capital Management & 14 others	74/100
7th	Pfizer 1849, New York City (United States), Public	Provider of pharmaceutical products for multiple disease treatments	-	Alcor Fund, Benson Family Private Equity ... & 16 others	72/100
8th	Roivant Sciences 2014, New York City (United States), Public	Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases	$1.3B	SoftBank Vision Fund, NovaQuest Capital Management ... & 7 others	72/100
9th	Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public	Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others	-	BB Biotech, Gershon Capital & 7 others	71/100
10th	Novartis 1996, Basel (Switzerland), Public	R&D focused on manufacturing of drugs for multiple therapeutic areas	-	Digital Pharma Lab, MT Capital & 9 others	70/100
202nd	Virchow Biotech 2001, Hyderabad (India), Funding Raised	Recombinant products for wound care, osteoporosis & periodontal disorders	-	Department of Biotechnology, BIRAC	34/100